{"entity":{"id":"nct02696356","kind":"trial","name":"Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma","aka":[],"tldr":"A phase 1 trial of GRN-1201 run by BrightPath Biotherapeutics, completed.","summary":"Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma is a phase 1 interventional study registered as NCT02696356 by BrightPath Biotherapeutics, with 18 participants enrolled, started 2016-04. Conditions recorded: Melanoma. Interventions recorded: GRN-1201.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02696356","url":"https://clinicaltrials.gov/study/NCT02696356"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["grn-1201"],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02696356","phase":"1","setting":"A Phase 1, Open-Label, Multi-Center, Multi-Dose Study of Intradermal GRN-1201 in HLA-A*02 Subjects With Resected Stage IIb, IIc or III Melanoma","sponsor":"BrightPath Biotherapeutics","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02696356/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"grn-1201","kind":"drug","name":"GRN-1201","route":"/drugs/grn-1201/"}],"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}]}}